Li, Cheng
Zhang, Baike
Tan, Xiao
Jia, Yong
Guo, Lisha
Wang, Chunlei
Xing, Yaofan
Li, Qiaoyun
Tian, Xuemin
Article History
Received: 30 November 2022
Accepted: 8 April 2023
First Online: 4 May 2023
Declarations
:
: The authors have no relevant financial or non-financial interests to disclose.
: The prospective observational clinical study protocol was approved by the Institutional Review Board and Ethics Committee and registered as a clinical research center in the 988th Hospital of People’s Liberation Army Joint Logistic Force, China (9882019000). It adhered strictly to the principles of the World Medical Association’s Declaration of Helsinki of the World Medical Association. All patients were provided with an explanation of the purpose and design of the study, and they were informed that FCB scleral buckling is still an off-label treatment for RRD. The patients provided written informed consent before participating in the study.
: Not applicable.